Meyer Handelman Co. cut its holdings in Becton Dickinson and Co (NYSE:BDX) by 7.7% in the third quarter, Holdings Channel reports. The fund owned 28,407 shares of the medical instruments supplier’s stock after selling 2,361 shares during the quarter. Meyer Handelman Co.’s holdings in Becton Dickinson and were worth $7,414,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Acropolis Investment Management LLC acquired a new stake in shares of Becton Dickinson and in the third quarter worth $101,000. Almanack Investment Partners LLC. acquired a new stake in shares of Becton Dickinson and in the second quarter worth $105,000. Truvestments Capital LLC acquired a new stake in shares of Becton Dickinson and in the third quarter worth $105,000. Bartlett & Co. LLC lifted its stake in shares of Becton Dickinson and by 2,900.0% in the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock worth $108,000 after buying an additional 435 shares during the last quarter. Finally, Bridgeworth LLC acquired a new stake in shares of Becton Dickinson and in the second quarter worth $131,000. Hedge funds and other institutional investors own 92.60% of the company’s stock.
A number of brokerages have recently weighed in on BDX. Piper Jaffray Companies reduced their price objective on shares of Becton Dickinson and to $250.00 and set an “overweight” rating for the company in a research note on Tuesday. Barclays set a $260.00 price objective on shares of Becton Dickinson and and gave the stock a “hold” rating in a research note on Thursday. Wells Fargo & Co reduced their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday. KeyCorp boosted their price objective on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Citigroup boosted their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the stock a “buy” rating in a research note on Wednesday, August 8th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $254.07.
In related news, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the completion of the transaction, the executive vice president now directly owns 13,318 shares in the company, valued at approximately $3,227,750.48. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction on Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total transaction of $9,956,940.00. Following the transaction, the director now owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The disclosure for this sale can be found here. 1.00% of the stock is owned by corporate insiders.
NYSE:BDX opened at $243.26 on Friday. The firm has a market cap of $63.38 billion, a P/E ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19. Becton Dickinson and Co has a one year low of $209.91 and a one year high of $265.87. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95.
Becton Dickinson and (NYSE:BDX) last released its earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $2.93. The firm had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The business’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the company earned $2.40 EPS. As a group, analysts forecast that Becton Dickinson and Co will post 12.2 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/11/10/meyer-handelman-co-has-7-41-million-holdings-in-becton-dickinson-and-co-bdx.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.